February 2019
NINDS: NeuroNEXT Clinical Trials (U01 - Clinical Trial Optional)
Deadlines: February 5, 2020; June 5, 2020; October 5, 2020
NIH: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) - Clinical Trial Optional
Deadlines: February 11, 2020
NIH: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3) - Clinical Trial Optional
Deadlines: February 11, 2020
NINDS: NINDS CREATE Bio Development Track: Preclinical Development for Biotechnology Products and Biologics (U01 - Clinical Trial Optional)
Deadlines: February 13, 2020, and July 20, 2020
NINDS: CREATE Bio Development Track: Preclinical and Early-Phase Clinical Development for Biologics (U44 SBIR- Clinical Trial Optional)
Deadlines: February 13, 2020, and July 20, 2020
NINDS: Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)
Deadlines: February 14, 2020; and July 20, 2020
NINDS: Clinical Validation of Candidate Biomarkers for Neurological Diseases (U01 Clinical Trial Optional)
Deadlines: February 14, 2020; and July 20, 2020
NINDS: Clinical Trial Readiness for Rare and Neurologial and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)
Deadlines: February 19, 2020; August 19, 2020; February 17, 2021; August 18, 2021; February 16, 2022
NINDS: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
Deadlines: February 19, 2020, June 17, 2020, October 20, 2020 and February 17, 2021
NINDS: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
Deadlines: February 19, 2020, June 17, 2020, October 20, 2020 and February 17, 2021
NINDS: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
Deadlines: February 19, 2020, June 17, 2020, October 20, 2020 and February 17, 2021